CG
TVRD

Cutler Group’s Tvardi Therapeutics TVRD Stock Holding History

Cutler Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-222
Closed -$1K – 5828
2022
Q1 		$1K Sell
222
-86
-28% -$35.3K ﹤0.01% 5137
2021
Q4 		$5K Buy
308
+89
+41% +$44.7K ﹤0.01% 4249
2021
Q3 		$9K Sell
219
-39
-15% -$19.6K ﹤0.01% 4065
2021
Q2 		$5K Buy
+258
New +$163K ﹤0.01% 4502
2018
Q4 		– Sell
-553
Closed -$28K – 4717
2018
Q3 		$28K Buy
553
+92
+20% +$66.4K ﹤0.01% 2037
2018
Q2 		$26K Buy
461
+386
+515% +$196K ﹤0.01% 2022
2018
Q1 		$1K Sell
75
-125
-63% -$60.6K ﹤0.01% 4214
2017
Q4 		$3K Sell
200
-556
-74% -$253K ﹤0.01% 4018
2017
Q3 		$16K Sell
756
-1,022
-57% -$512K ﹤0.01% 3364
2017
Q2 		$41K Sell
1,778
-641
-26% -$407K ﹤0.01% 2701
2017
Q1 		$229K Buy
2,419
+497
+26% +$266K 0.01% 1090
2016
Q4 		$155K Sell
1,922
-420
-18% -$135K 0.01% 1523
2016
Q3 		$110K Buy
2,342
+2,156
+1,159% +$467K ﹤0.01% 1730
2016
Q2 		$2K Buy
+186
New +$40.5K ﹤0.01% 5797
2016
Q1 		– Sell
-94
Closed -$5K – 7347
2015
Q4 		$5K Buy
+94
New +$51.6K ﹤0.01% 4960

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutler Group's TVRD Position: Q1 2023 in Review

Cutler Group sold out of Tvardi Therapeutics (TVRD) in Q1 2023, closing a stake of 17 shares — an estimated $6K sold.

Cutler Group first reported a position in TVRD in Q4 2015 and held it in 24 quarters. The position peaked at $316K in Q1 2017. 162 funds tracked by Wall St. Rank hold TVRD as of Q1 2023.

  • Cutler Group reported no remaining Tvardi Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 17 Tvardi Therapeutics shares in Q1 2023, an estimated $6K.
  • Cutler Group first reported a position in Tvardi Therapeutics in Q4 2015 and held it in 24 quarters.
  • Cutler Group's Tvardi Therapeutics position peaked at $316K in Q1 2017.
  • 162 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.